Catalyst Wire Dossier Catalyst Wire Dossier

RTA 408 ophthalmic suspension

omaveloxolone · Reata Pharmaceuticals
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for RTA 408 ophthalmic suspension, covering 2023-04-19 to 2023-05-26. Get the full timeline:

Most recent: Clinical Trial Update: RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD [Phase 2]

See pricing